Sidra Medicine announces first GCC use of naxitamab and first Qatar use of dinutuximab beta
Published · Updated
What happened
Sidra Medicine announced that it had administered naxitamab for the first time in the GCC and dinutuximab beta for the first time in Qatar for children with high-risk neuroblastoma.
Why it matters
The development adds a new specialized treatment capability in-country for a rare pediatric cancer and can reduce reliance on external referral for some cases. It also creates follow-on requirements for drug supply, trained staff, toxicity management, and payer or public-funding decisions if the treatment is to be offered beyond isolated cases.
Sidra Medicine said on October 1 that its teams administered naxitamab (Danyelza®) for the first time in the Gulf and dinutuximab beta (Qarziba®) for the first time in Qatar to treat high-risk neuroblastoma. The announcement marks a discrete expansion of Qatar's pediatric oncology capability inside the country rather than through overseas referral. For health leadership, the immediate question is whether to treat this as a limited first-use milestone or to operationalize it into a recurring service line with the staffing, procurement, and referral pathways that follow.
Watch for
Sidra Medicine publication on or after 2026-10-02 detailing patient pathway, multidisciplinary protocol, or additional administered cases Qatar Ministry of Public Health statement on or after 2026-10-02 confirming national referral or reimbursement arrangements for high-risk neuroblastoma immunotherapy Hamad Medical Corporation or Sidra Medicine posting on or after 2026-10-02 for pediatric oncology pharmacy, infusion, or immunotherapy nursing roles linked to neuroblastoma care No new Sidra Medicine clarification by 2026-10-05 on treatment continuity, case volume, or supply arrangements for naxitamab and dinutuximab beta
Researched and written by AI from the sources listed, under published rules. How V³ Aware is made